GSK takes USD300 million stake in 23andMe

GSK takes USD300 million stake in 23andMe
The collaboration with GlaxoSmithKline will enable 23andMe to deliver cures or treatments for diseases, says Anne Wojcicki, 23andMe's chief executive officer and co-founder

26 July 2018 - Deborah Wilkes

GlaxoSmithKline has announced a four-year collaboration with 23andMe, and is taking a USD300 million stake in the privately-held consumer genetics and research company.

Commenting on the collaboration, GlaxoSmithKline said the exclusive arrangement would focus on "research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery".

"The collaboration will combine 23andMe's large-scale genetic resources and advanced data science skills with the scientific and medical knowledge and commercialisation expertise of GlaxoSmithKline," added the company.

GlaxoSmithKline said the collaboration would "identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes".

Founded in 2006, 23andMe provides genetic tests that allow people to find out more about their health and ancestry. Customers can also participate in research and contribute their information to a database, which GlaxoSmithKline said was now the "world's largest genetic and phenotypic resource".

More than five million customers

GlaxoSmithKline said the US-based company had more than five million customers.

Hal Barron – GlaxoSmithKline's chief scientific officer and president research and development – said partnering with 23andMe would shift the company's research and development organisation to be "driven by genetics".

Anne Wojcicki, 23andMe's chief executive officer and co-founder, said the collaboration would enable the company to "deliver what many customers have been asking for – cures or treatments for diseases".

Under the terms of the deal, GlaxoSmithKline and 23andMe have entered into a four-year collaboration with the option to extend for a fifth year. GlaxoSmithKline will be 23andMe's exclusive collaborator for drug target discovery programmes.

GlaxoSmithKline is contributing its LRRK2 inhibitor, which is currently in preclinical development as a potential treatment for Parkinson's disease, into the collaboration.

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* Premium News Stories
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE

Click tags below for more information on topics:

GlaxoSmithKline

Back to Industry News

Share this page: